Condition: Immune Related Adverse Events · Immune-Mediated Hepatitis · Cancer · Sponsor: University Hospital, Basel, Switzerland
This study evaluates the effectiveness of low-dose corticosteroids in managing grade 2-3 immune-related hepatitis in cancer patients treated with immune checkpoint inhibitors. It aims to determine whether of 0.5-1miligram per kilogram bodyweight prednisolone is sufficient to manage immune-related hepatitis without the need for dose escalation or additional immunosuppressive therapy.
This description comes directly from the study's public registry record.
Andreas M Schmitt, MD · +41 61 265 50 74 · andreasmichael.schmitt@usb.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel | Basel, Canton of Basel-City, Switzerland | Recruiting |
| Royal Marsden Hospital | London, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07167251